Live Breaking News & Updates on Slamon Research Laboratory

Stay updated with breaking news from Slamon research laboratory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,. ....

Dave Licata , Vince Ruiz , Ribociclib Kisqali , Mark Alles , Palbociclib Ibrance , Dennis Slamon , Perceptive Xontogeny Venture Fund , Slamon Research Laboratory , Bristol Myers Squibb , Division Of Hematology Oncology , Roth Zabel , Crandon Law , David Geffen School Of Medicine , Deep Track Capital , Perceptive Advisors , Avidity Partners , Goldman Sachs Alternatives , Vertex Ventures , Moore Strategic Ventures , Blue Owl Healthcare Opportunities , Notch Ligand , Rebecca Luse , Deep Track , Board Member , Scientific Co Founder Dennis Slamon , Geffen School ,